|Bid||196.00 x 800|
|Ask||0.00 x 800|
|Day's range||179.67 - 195.61|
|52-week range||70.00 - 331.68|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||258.00|
Any way you look at it, Moderna (NASDAQ: MRNA) is on a roll. Here's why Moderna just booked another $3 billion in vaccine orders and no one seemed to care. Moderna announced last week that the U.S. government was buying another 200 million doses of its COVID-19 vaccine.
Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
On June 14, Novavax (NASDAQ: NVAX) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups. Shares fell about 10% after Novavax published the results.